sr141716 has been researched along with pf 514273 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Black, SC; Carpino, PA; DaSilva-Jardine, P; Dow, RL; Griffith, DA; Hadcock, JR; Iredale, PA; Nduaka, CI; O'Connor, RE; Paight, ES; Schneider, SR; Scott, DO | 1 |
| Carpino, PA; Dow, RL; Gautreau, D; Hadcock, JR; Iredale, PA; Kelly-Sullivan, D; Lizano, JS; O'Connor, RE; Schneider, SR; Scott, DO; Ward, KM | 1 |
2 other study(ies) available for sr141716 and pf 514273
| Article | Year |
|---|---|
Discovery of 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one (PF-514273), a novel, bicyclic lactam-based cannabinoid-1 receptor antagonist for the treatment of obesity.
Topics: Animals; Clinical Trials as Topic; Crystallography, X-Ray; Drug Discovery; Humans; Lactams; Obesity; Oxazepines; Pyrazoles; Rats; Receptor, Cannabinoid, CB1 | 2009 |
Design of a Potent CB1 Receptor Antagonist Series: Potential Scaffold for Peripherally-Targeted Agents.
Topics: | 2012 |